Your session is about to expire
← Back to Search
INCB000928 for Stone Man Syndrome (Progress Trial)
Progress Trial Summary
This trial is testing a new drug to treat fibrodysplasia ossificans progressiva, a rare disorder that causes the body's muscles and connective tissue to turn into bone.
Progress Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowProgress Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Progress Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I am 12 or older and have been diagnosed with FOP.You are willing to prevent pregnancy or becoming a parent based on the conditions described below.I can have a full-body CT scan without needing a breathing tube.I am currently on treatment for a long-term or active infection.I am infected with HIV, HBV, or HCV.
- Group 1: Group A: INCB000928
- Group 2: Group B: Placebo followed by INCB000928
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
How many individuals are being asked to participate in this clinical trial?
"The sponsor, Incyte Corporation, needs to enroll 60 eligible patients from different hospitals including Investigative Site US002 in Philadelphia, Pennsylvania and Investigative Site US004 in Rochester, Minnesota."
Who would be a good candidate to join this experiment?
"Myositis ossificans patients aged 12 to 99 are encouraged to apply for this trial, of which there are 60 slots available."
Are pediatric patients allowed in this particular research program?
"Eligibility criteria for this study includes being between 12 to 99 years old."
Are there still opportunities for people to participate in this research?
"If you're interested, this trial might be for you. The information was first posted on May 5th, 2022 and the most recent update was October 17th, 2022."
Can you please provide more details on the potential side effects of INCB000928?
"INCB000928's safety scores a 2 because, while there is evidence that it is safe, there is no data supporting its efficacy."
Share this study with friends
Copy Link
Messenger